A Phase 4 interventional study of Verteporfin Photodynamic Therapy and Ranibizumab in Polypoidal Choroidal Vasculopathy, sponsored by Novartis. Completed at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-19.
Sponsored by Novartis · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to compare the efficacy of ranibizumab and verteporfin PDT combination treatment and verteporfin PDT monotherapy vs.ranibizumab monotherapy alone in achieving complete regression of polyps in patients with symptomatic macular polypoidal choroidal vasculopathy.
54 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 6 are open to participants now.
This study's enrollment of 61 is above the median of 50 across 39 interventional studies indexed under Polypoidal Choroidal Vasculopathy.
Browse Polypoidal Choroidal Vasculopathy studies →Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Inclusion criteria for study eye:
Exclusion Criteria:
Exclusion criteria for study eye:
Prior Ocular treatment:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Photodynamic therapy with verteporfin in combination with ranibizumab injection. Patients received one treatment at baseline with verteporfin photodynamic therapy (PDT) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
Drug: Verteporfin Photodynamic Therapy · Drug: Ranibizumab
Patients received one treatment at baseline with verteporfin photodynamic therapy in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab placebo (sham intravitreal injection) on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
Drug: Verteporfin Photodynamic Therapy
Patients received one treatment at baseline with verteporfin placebo (with sham photodynamic therapy) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
Drug: Ranibizumab
After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, light application of 50 J/cm\^2 to the study eye was begun 15 minutes after the start of infusion.
Also known as: Visudyne
Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.
Also known as: Lucentis
Number of Participants With Complete Regression (CR) of Polyps Measured by Indocyanine Green Angiography (ICGA)
Indocyanine green angiography (ICGA) assessments were performed using the Heidelberg Retinal Angiography 2 (HRA2) machine to measure the Total Lesion Area and the degree of polyp regression. Complete regression was defined as no polyps seen on the imaging.
Time frame: Month 6
Number of Participants With at Least One Complete Polyp Regression During 6 Months Assessed by ICGA
Indocyanine green angiography (ICGA) assessments were performed using the Heidelberg Retinal Angiography 2 (HRA2) machine to measure the Total Lesion Area and the degree of polyp regression. Complete regression was defined as no polyps seen on the imaging.
Time frame: Baseline through end of study (6 months)
Mean Change From Baseline in Central Retinal Thickness Measured by Optic Coherence Tomography (OCT)
High resolution 6 meridian scans were performed to measure central retinal thickness.
Time frame: Baseline and Month 6
Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 6
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.
Time frame: Baseline and Month 6
| Milestone | Verteporfin and Ranibizumab | Verteporfin Monotherapy | Ranibizumab Monotherapy |
|---|---|---|---|
| Started | 19 | 21 | 21 |
| Completed | 18 | 20 | 21 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
Indocyanine green angiography (ICGA) assessments were performed using the Heidelberg Retinal Angiography 2 (HRA2) machine to measure the Total Lesion Area and the degree of polyp regression. Complete regression was defined as no polyps seen on the imaging.
| Participants | Verteporfin and Ranibizumab | Verteporfin Monotherapy | Ranibizumab Monotherapy |
|---|---|---|---|
| Number of Participants With Complete Regression (CR) of Polyps Measured by Indocyanine Green Angiography (ICGA) | 14 | 15 | 6 |
Indocyanine green angiography (ICGA) assessments were performed using the Heidelberg Retinal Angiography 2 (HRA2) machine to measure the Total Lesion Area and the degree of polyp regression. Complete regression was defined as no polyps seen on the imaging.
| Participants | Verteporfin and Ranibizumab | Verteporfin Monotherapy | Ranibizumab Monotherapy |
|---|---|---|---|
| Number of Participants With at Least One Complete Polyp Regression During 6 Months Assessed by ICGA | 15 | 18 | 9 |
High resolution 6 meridian scans were performed to measure central retinal thickness.
| micrometers | Verteporfin and Ranibizumab | Verteporfin Monotherapy | Ranibizumab Monotherapy |
|---|---|---|---|
| Baseline | 324.1 ± 112.72 | 285.3 ± 105.64 | 268.5 ± 97.84 |
| Change from Baseline at month 6 | -145.6 ± 118.97 | -98.1 ± 104.33 | -65.7 ± 114.32 |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.
| Letters | Verteporfin and Ranibizumab | Verteporfin Monotherapy | Ranibizumab Monotherapy |
|---|---|---|---|
| Baseline | 59.8 ± 16.21 | 57.2 ± 12.76 | 49.0 ± 18.05 |
| Change from Baseline at Month 6 | 10.9 ± 10.92 | 7.5 ± 10.65 | 9.2 ± 12.39 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Verteporfin and Ranibizumab | — | 1/19 (5.3%) | 8/19 (42.1%) |
| Verteporfin Monotherapy | — | 1/21 (4.8%) | 9/21 (42.9%) |
| Ranibizumab Monotherapy | — | 2/21 (9.5%) | 4/21 (19%) |
| Event | Verteporfin and Ranibizumab | Verteporfin Monotherapy | Ranibizumab Monotherapy |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/19 | 0/21 | 0/21 |
| Angina pectorisCardiac disorders | 0/19 | 0/21 | 1/21 |
| Biliary tract infectionInfections and infestations | 0/19 | 1/21 | 0/21 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/19 | 1/21 | 0/21 |
| DizzinessNervous system disorders | 0/19 | 0/21 | 1/21 |
| Event | Verteporfin and Ranibizumab | Verteporfin Monotherapy | Ranibizumab Monotherapy |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/19 | 4/21 | 0/21 |
| Retinal haemorrhage (Study eye)Eye disorders | 2/19 | 3/21 | 0/21 |
| ToothacheGastrointestinal disorders | 2/19 | 0/21 | 0/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/19 | 0/21 | 0/21 |
| Conjunctival hyperaemia (Study eye)Eye disorders | 1/19 | 0/21 | 0/21 |
| Dry eye (Study eye)Eye disorders | 1/19 | 1/21 | 0/21 |
| Macular oedema (Study eye)Eye disorders | 1/19 | 0/21 | 0/21 |
| Polypoidal choroidal vasculopathy (Fellow eye)Eye disorders | 1/19 | 0/21 | 0/21 |
| Visual impairment (Study eye)Eye disorders | 1/19 | 0/21 | 0/21 |
| Dental cariesGastrointestinal disorders | 1/19 | 0/21 | 0/21 |
| Age Continuous(years) | Verteporfin and Ranibizumab | Verteporfin Monotherapy | Ranibizumab Monotherapy | Total |
|---|---|---|---|---|
| Mean | 63.8 ± 8.30 | 62.2 ± 9.77 | 69.3 ± 8.27 | 65.1 ± 9.21 |
| Sex: Female, Male(Participants) | Verteporfin and Ranibizumab | Verteporfin Monotherapy | Ranibizumab Monotherapy | Total |
|---|---|---|---|---|
| Female | 8 | 6 | 6 | 20 |
| Male | 11 | 15 | 15 | 41 |
The record gives a start of Apr 2008 and a primary completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Verteporfin · Ranibizumab
Polypoidal Choroidal Vasculopathy →